Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 7/20 | 0.66 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 6/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
| ▸ | ULK1 | O75385 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448802 | 0.82 | IGF1R (0.58) | IGF1RCHEK1NTRK2HDAC3HDAC1 | |
| SCHEMBL3345672 | 0.81 | IGF1R (0.57) | IGF1RCHEK1NTRK2HDAC3HDAC1 | |
| SCHEMBL3344762 | 0.81 | IGF1R (0.57) | IGF1RCHEK1NTRK2HDAC3HDAC1 | |
| SCHEMBL11345551 | 0.80 | IGF1R (1.00) | IGF1RCHEK1NTRK2HDAC3HDAC1 | |
| SCHEMBL3348225 | 0.79 | IGF1R (0.55) | IGF1RCHEK1NTRK2HDAC3HDAC1 | |
| SCHEMBL3447342 | 0.78 | IGF1R (0.54) | IGF1RCHEK1NTRK2HDAC3HDAC1 | |
| Hydrochloric Acid SCHEMBL3449249 | 0.77 | IGF1R (0.53) | IGF1RCHEK1NTRK2HDAC3HDAC1 | |
| SCHEMBL3450454 | 0.76 | IGF1R (0.55) | IGF1RCHEK1NTRK2HDAC3HDAC1 | |
| SCHEMBL3451135 | 0.76 | IGF1R (0.53) | IGF1RCHEK1NTRK2PTK2 | |
| SCHEMBL1039787 | 0.76 | EGFR (0.59) | IGF1RPTK2CDK19ALKULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | IGF1R 4845/4885CHEK1 3477/4885NTRK2 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.